Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Insulin Resistance & MCAS: The Bidirectional Link Explained #shorts

9 Jun 2026 · 1 min

Watch on YouTube

0:45

In this brief conversational clip, Dr. Robert Whitfield explains the two-way relationship between insulin resistance and mast cell activation syndrome (MCAS). He notes that insulin resistance can trigger MCAS and that MCAS can, in turn, cause insulin resistance. Hormonal changes specific to women—such as puberty, perimenopause, and menopause—can exacerbate MCAS flares, making blood‑sugar regulation especially critical for female patients. The discussion then turns to GLP‑1 based therapies: these agents not only improve insulin sensitivity but also directly bind to GLP‑1 and GIP receptors on mast cells, dampening mast cell activation and thereby addressing both conditions simultaneously.

Chapters

Insulin resistance is a huge trigger for MCAS and vice versa. MCAS is often a cause of insulin resistance. We know internally though, hormonal imbalances, hormonal changes for women in puberty, in perimenopause, menopause, those times can be really tricky for women. They often are, you know, flare if they have MCAS. So getting the hormones under control, insulin resistance is a huge trigger for, for MCAS and vice versa. MCAS is often a cause of insulin resistance. And so there's a bidirectional relationship there. And that— so blood sugar regulation is often— can be triggering.
So now you're going to get the— do the GLP-1s help mast cell activation syndrome?
Yeah.
Because they decrease insulin resistance.
But they also bind directly to the mast cells. Mast cells have GLP receptors and GIP receptors. So it's literally just binding and sending a signal, stop. That's actually helping the insulin resistance as well because now the mast cells are not activated.